Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: while there is a net profit and improved operating loss, total net revenues have significantly decreased. The Q&A section highlighted strategic uncertainties and lack of specific guidance, which could unsettle investors. The shareholder return plan and improved financial metrics are positive, but the overall sentiment remains neutral due to revenue decline and strategic ambiguities.
Key Financial Performance
Total Net Revenues EUR 6.5 million compared to EUR 75 million in Q1 2025, a significant decrease mainly driven by the prior year comparison, which included EUR 57.6 million related to the OLCA revenue recognition. The remaining deferred income balance related to the OLCA was fully released at year-end 2025.
Supply Revenues EUR 4.9 million in supply revenues from Jyseleca inventory sales to Alfasigma.
Collaboration Revenues EUR 1.6 million in collaboration revenues, reflecting royalties from Gilead.
R&D Expenses Decreased to EUR 31 million, contributing to an overall improvement in the cost base. This reduction is driven by lower severance expenses and the absence of restructuring-related charges that impacted Q1 2025.
Operating Loss Improved to EUR 63.7 million compared to EUR 158.7 million last year, which included EUR 111 million in restructuring costs.
Net Financial Income EUR 77.7 million, mainly driven by positive fair value adjustments and favorable unrealized currency exchange gains on U.S. dollar-denominated cash and investments of EUR 64.3 million.
Net Profit EUR 14.5 million for the quarter compared to a net loss of EUR 153.4 million for the first 3 months of 2025.
Financial Investments and Cash and Cash Equivalents EUR 2,982.2 million on March 31, 2026, as compared to EUR 3,297 million on March 31, 2025. The quarter-end cash balance benefited from a decrease in the U.S. dollar to euro exchange rate, which moved from $1.175 at year-end 2025 to approximately $1.15 at the end of the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Gamgertamig: A BCMA/CD3 T cell engager for autoimmune diseases with multibillion-dollar revenue potential. Currently in Phase Ib dose-ranging studies and expected to enter registrational studies by 2027. Demonstrated compelling clinical data across 5 autoimmune indications, with rapid induction of durable complete responses and minimal cytokine release syndrome. Received Fast Track and Orphan drug designation in the U.S. for ITP and AHA.
Partnership with Gilead: Entered into a binding agreement with Gilead regarding Ouro Medicines' portfolio, including gamgertamig and three preclinical programs. This partnership is expected to drive significant shareholder value and expand the company's market presence.
Financial Flexibility: Secured $500 million for broader use beyond Ouro investment, with up to $150 million available for shareholder returns. Improved financial terms with Gilead, enhancing strategic and financial flexibility.
Cost Reduction: R&D expenses decreased to EUR 31 million, contributing to an improved cost base. Operating loss reduced to EUR 63.7 million compared to EUR 158.7 million last year.
Rebranding to Lakefront Biotherapeutics: The company is undergoing a transformation, including a name change to Lakefront Biotherapeutics, symbolizing a new beginning and strategic shift.
Board and Leadership Changes: Appointed Gino Santini as the new Board Chair, bringing extensive pharmaceutical and business development expertise to guide the company's strategic direction.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company's total net revenues decreased significantly from EUR 75 million in Q1 2025 to EUR 6.5 million in Q1 2026, primarily due to the absence of OLCA revenue recognition.
High Operating Loss: Despite improvements, the company still reported an operating loss of EUR 63.7 million for Q1 2026, which could impact financial stability.
Ouro Transaction Costs: The company expects to spend EUR 775 million to EUR 790 million on Ouro-related cash expenditures in 2026, which includes upfront payments and operating costs, potentially straining cash reserves.
Cell Therapy Wind-Down Costs: The company anticipates one-time cash costs of EUR 125 million to EUR 175 million related to the wind-down of cell therapy activities, adding to financial burdens.
Dependence on Gilead Collaboration: The company's financial flexibility and strategic opportunities are partially tied to the revised terms of its collaboration with Gilead, which could limit independence.
Currency Exchange Risks: The company's financial results are influenced by currency exchange rates, as seen in the favorable unrealized currency exchange gains in Q1 2026, which could reverse in the future.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Gamgertamig Development Timeline: The lead program, gamgertamig, is expected to enter registrational studies as early as 2027. The program has received Fast Track and Orphan drug designation in the U.S. for ITP and AHA, supporting an accelerated development path.
Gamgertamig Market Potential: Gamgertamig has multibillion-dollar revenue potential and may address over 20 separate indications, providing a pipeline and product opportunity.
Ouro Transaction Financial Guidance: The company expects to spend EUR 775 million to EUR 790 million on Ouro-related cash expenditures in 2026, including operating costs and transaction expenses.
Cash and Cash Equivalents Outlook: The company expects to end 2026 with EUR 1.975 billion to EUR 2.05 billion of cash and cash equivalents, inclusive of Ouro-related expenditures and the wind-down of cell therapy activities.
Strategic Financial Flexibility: Up to EUR 150 million of the EUR 500 million unlocked from the revised Gilead agreement may be used for shareholder returns, with the remainder available for strategic transactions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Approval: The company received approval from shareholders to complete a share repurchase.
Potential Share Repurchase: The company will provide an update regarding a potential share repurchase following the close of the Ouro transaction.
Capital Allocation for Shareholder Returns: Up to $150 million of the $500 million unlocked from the revised terms with Gilead may be used for return of capital to shareholders, subject to certain limitations.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the latest thoughts on what the dose-ranging gamgertamig data will need to show to move forward in registrational trials?
A:The optimal profile for late-stage development would involve profound B-cell depletion with a dose duration schedule that minimizes CRS risk. The dose should result in deep but relatively short B-cell depletion to minimize infectious risk and the need for supplemental intravenous immunoglobulin. By 2027, the company expects to be comfortable with the doses for Phase III programs.
Q:How does the company view the evolution of the BCMA/CD3 space and its development plans?
A:The company believes gamgertamig is the best-in-class alternative and has a clear timing advantage in sizable indications. They are encouraged by the investment in the space and believe the market may either split among various assets or be dominated by the best drug. They are actively exploring multiple indications.
Q:How is gamgertamig differentiated structurally or otherwise from other BCMA/CD3s?
A:Gamgertamig has a detuned CD3 binding arm to reduce CRS risk and a potent BCMA binding arm for deep B-cell depletion. These features result in profound B-cell depletion and clinical responses.
Q:What is the framework for evaluating and prioritizing indications for pivotal development of gamgertamig?
A:The framework includes selecting indications with a mechanistic hypothesis that deep B-cell depletion will provide clinical benefit, focusing on diseases with inadequate standard of care, sizable patient populations, and feasible clinical trials. The goal is to demonstrate the broad potential of the technology.
Q:What are the company’s plans for continued business development (BD) activities and prioritization?
A:The company has substantial capital for future BD but has set a high hurdle for the next deal. They are focused on executing current programs and are in no rush for additional BD deals. They may consider opportunities that synergize with gamgertamig in autoimmune diseases.
Q:What is the company’s view on infection risk and hematology events associated with gamgertamig and the BCMA-TCE class?
A:The infectious risk is tied to the duration of B-cell and plasma cell depletion. The current dosing schedule aims to optimize the period of B-cell depletion to make the infectious risk manageable. The team has worked on dose ranging to minimize these risks.
Q:What are the strategic options being considered for the Galapagos 3667 program?
A:The company is analyzing various alternatives for the Galapagos 3667 program and is close to making a decision. They are assessing a broad range of options but did not provide specific details.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details on the strategic options for the Galapagos 3667 program, stating only that the process is well advanced and a decision will be made soon. They also deferred commenting on whether the BCMA/CD3 market will be dominated by one drug or split among various assets, stating that it will be addressed further down the line.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agreement
Chair
Chief
OLCA
Officer
advantage
agreement Gilead
background
capital allocation
cash equivalent
cash expenditure
cell engager
closing transaction
cost
decrease
development expertise
dollar
experience
gamgertamig
indication
legacy
loss EUR
modification term
pharmaceutical
potential
press release
proof concept
reduction
relationship
restructuring
revenue EUR
share repurchase
story
waiver modification
wind cell
GLPG Transcript
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals mixed signals: while there is a net profit and improved operating loss, total net revenues have significantly decreased. The Q&A section highlighted strategic uncertainties and lack of specific guidance, which could unsettle investors. The shareholder return plan and improved financial metrics are positive, but the overall sentiment remains neutral due to revenue decline and strategic ambiguities.
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call reveals several negative factors: significant financial impacts from the cell therapy wind-down, strategic reorganization costs, and currency exchange risks. Although there is a strong cash position and improved operating profit, the dependency on Gilead and lack of clear guidance on cost management raise concerns. The Q&A section highlights management's avoidance of specifics on cost reduction and breakeven timelines, adding uncertainty. These factors, combined with the strategic reorganization costs and potential financial challenges, suggest a negative stock price movement in the next two weeks.
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents mixed signals. Financial performance shows a decrease in cash and interest income, but strategic currency shifts and stable income from royalties are positives. The Q&A highlights a focus on strategic partnerships, particularly with Gilead, but lacks clarity on deal specifics and internal pipeline strategies. The absence of strong guidance or new partnership announcements tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Positive10-31
The earnings call presents a stable financial position with a significant cash reserve and a net profit, despite a high cash burn rate. The strategic partnerships and regulatory progress in CAR-T therapies, along with a focus on oncology and immunology, are positive indicators. The Q&A reveals confidence in addressing potential therapy side effects and ongoing business development. However, some concerns remain about competitive pressures and logistical challenges. Overall, the sentiment is positive, with potential for stock price growth driven by strategic advancements and strong cash management.
GLPG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
